UBS initiates coverage of Ocular Therapeutix with buy rating and $14 target
OCUL•UBS initiated coverage of Ocular Therapeutix with a buy rating and a $14 target price.
Related News
IREN climbs as Anthropic reportedly enters multi-year cloud deal
IREN•
Nasdaq trade halt: volatility trading pause at 10:45 am
YMAT•
BioAge Labs, Inc.: UBS initiates coverage with neutral rating and $8 target price
BIOA•
Nasdaq trade halt continues; reason not available at 9:35 a.m.
UCFI•
Nasdaq halts WFF trading for volatility at 9:38 a.m.
WFF•